News
03-11-2010, 06:23 AM
Peregrine Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing innovative monoclonal antibodies for the treatment of cancer and serious viral infections, today announced financial results for the third quarter of fiscal year (FY) 2010 ended January 31, 2010. The company also provided an update on its clinical programs and corporate developments.
More... (http://www.news-medical.net/news/20100311/Peregrine-Pharmaceuticals-third-quarter-fiscal-2010-total-revenues-up-4525.aspx)
More... (http://www.news-medical.net/news/20100311/Peregrine-Pharmaceuticals-third-quarter-fiscal-2010-total-revenues-up-4525.aspx)